Contineum Therapeutics, Inc.

Contineum Therapeutics completed enrolment for its Phase II trial, PIPE-307 VISTA, targeting relapsing-remitting multiple sclerosis (RRMS) with 168 subjects. The trial evaluates PIPE-307's efficacy and safety, aiming for remyelination evidence. Results expected by Q3 this year. Also developing PIPE-791 for other conditions.

Contineum Therapeutics completed enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial for RRMS, aiming to assess safety and efficacy. The trial, a collaboration with Janssen Pharmaceutica NV, targets remyelination changes, with completion expected by Q3 2025.

Contineum Therapeutics completed enrollment for its Phase 2 PIPE-307 VISTA trial targeting 168 RRMS patients, aiming to assess the safety and efficacy of PIPE-307, a potential first-in-class M1 receptor antagonist. The trial, expected to conclude by Q3 2025, focuses on remyelination in RRMS patients.

The Privacy Policy outlines service details, personal data usage, processing, sharing, rights regarding personal data, and unsubscribing from marketing. Services target corporate subscribers, requiring a corporate email address.

In 2024, Multiple Sclerosis News Today highlighted key MS developments: updated McDonald criteria for diagnosis, limitations of anti-CD20 therapies in PPMS, high-dose vitamin D's potential to delay MS progression, FDA's breakthrough device designation for a myelin-repairing neurostimulator, promising experimental oral therapy PIPE-307, advancements in myelin-repairing treatments, ancient DNA's link to MS risk, long-term benefits of Mavenclad, obesity medications possibly lowering MS risk, and MS Awareness Month's focus on patient experiences.

Contineum Therapeutics, Inc. (CTNM), a clinical-stage biopharmaceutical company, focuses on developing oral small molecule therapies for neuroscience, inflammation, and immunology. Its lead assets include PIPE-791 for idiopathic pulmonary fibrosis and progressive MS, PIPE-307 for depression and MS, and CTX-343, an LPA1R antagonist. The company, formerly Pipeline Therapeutics, Inc., is based in San Diego, CA, and has a market cap of $344.649M.

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.